Compare
Dianthus Therapeutics, Inc. vs Camp4 Therapeutics Corp vs Bicycle Therapeutics PLC vs Nurix Therapeutics, Inc.
| Latest fiscal year | Dianthus Therapeutics, Inc. DNTH | Camp4 Therapeutics Corp CAMP | Bicycle Therapeutics PLC BCYC | Nurix Therapeutics, Inc. NRIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-11-30 |
| Revenue | $2.04M | $3.50M | $72.59M | $83.98M |
| Revenue growth (YoY) | -67.3% | +436.5% | +105.8% | +54.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | -340.4% | -340.2% |
| Net margin | n/m | n/m | -301.7% | -314.9% |
| Net income | -$162.34M | -$80.40M | -$218.96M | -$264.46M |
| EPS (Diluted) | -$4.20 | -$2.65 | -$3.16 | -$3.05 |
| Operating cash flow | -$129.06M | -$29.55M | -$249.68M | -$249.47M |
| Free cash flow | n/a | -$29.83M | -$252.03M | -$263.47M |
| Cash & equivalents | $51.09M | $109.52M | $628.11M | $246.96M |
| Total assets | $530.92M | $117.81M | $717.60M | $688.13M |
| Total liabilities | $37.52M | $70.10M | $107.62M | $149.39M |
| Shareholders' equity | $493.40M | $47.70M | $609.98M | $538.75M |
| Return on year-end equity | -32.9% | -168.5% | -35.9% | -49.1% |
| Shares outstanding | 43.22M | 51.90M | 69.37M | 101.81M |
Revenue, most recent five fiscal years
| Fiscal year | Dianthus Therapeutics, Inc. | Camp4 Therapeutics Corp | Bicycle Therapeutics PLC | Nurix Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $2.04M Ended 2025-12-31 | $3.50M Ended 2025-12-31 | $72.59M Ended 2025-12-31 | $83.98M Ended 2025-11-30 |
| 1 year earlier | $6.24M Ended 2024-12-31 | $652.0K Ended 2024-12-31 | $35.27M Ended 2024-12-31 | $54.55M Ended 2024-11-30 |
| 2 years earlier | $2.83M Ended 2023-12-31 | $350.0K Ended 2023-12-31 | $26.98M Ended 2023-12-31 | $76.99M Ended 2023-11-30 |
| 3 years earlier | n/a | n/a | $14.46M Ended 2022-12-31 | $38.63M Ended 2022-11-30 |
| 4 years earlier | n/a | n/a | $11.70M Ended 2021-12-31 | $29.75M Ended 2021-11-30 |